CL2016000009A1 - Tratamiento de rosacea papulopustular con ivermectina. - Google Patents

Tratamiento de rosacea papulopustular con ivermectina.

Info

Publication number
CL2016000009A1
CL2016000009A1 CL2016000009A CL2016000009A CL2016000009A1 CL 2016000009 A1 CL2016000009 A1 CL 2016000009A1 CL 2016000009 A CL2016000009 A CL 2016000009A CL 2016000009 A CL2016000009 A CL 2016000009A CL 2016000009 A1 CL2016000009 A1 CL 2016000009A1
Authority
CL
Chile
Prior art keywords
ivermectin
papulopustular rosacea
rosacea treatment
treatment
papulopustular
Prior art date
Application number
CL2016000009A
Other languages
English (en)
Inventor
Jean Jacovella
Jean-Paul Chappuis
Alexandre Kaoukhov
Michael Graeber
Laurence Salin
Michel Poncet
Philippe Briantais
Original Assignee
Galderma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52133217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000009(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galderma Sa filed Critical Galderma Sa
Publication of CL2016000009A1 publication Critical patent/CL2016000009A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J9/00—Feeding-bottles in general
    • A61J9/06—Holders for bottles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

USO DE UNA COMPOSICION FARMACEUTICA QUE COMPRENDE IVERMECTINA PARA EL TRATAMIENTO DE LA ROSACEA PAPULO-PUSTULAR.
CL2016000009A 2013-07-08 2016-01-05 Tratamiento de rosacea papulopustular con ivermectina. CL2016000009A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361843540P 2013-07-08 2013-07-08
US201361919208P 2013-12-20 2013-12-20
US201461927717P 2014-01-15 2014-01-15
US14/209,958 US9233118B2 (en) 2013-07-08 2014-03-13 Treatment of papulopustular rosacea with ivermectin

Publications (1)

Publication Number Publication Date
CL2016000009A1 true CL2016000009A1 (es) 2016-08-19

Family

ID=52133217

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2016000008A CL2016000008A1 (es) 2013-07-08 2016-01-05 Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
CL2016000009A CL2016000009A1 (es) 2013-07-08 2016-01-05 Tratamiento de rosacea papulopustular con ivermectina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2016000008A CL2016000008A1 (es) 2013-07-08 2016-01-05 Tratamiento de lesiones inflamatorias de rosacea con ivermectina.

Country Status (17)

Country Link
US (12) US9233117B2 (es)
EP (2) EP3019174A1 (es)
JP (8) JP6438466B2 (es)
KR (2) KR101864799B1 (es)
CN (4) CN111467301A (es)
AU (2) AU2014287408B2 (es)
BR (2) BR112016000350A8 (es)
CA (2) CA2916668A1 (es)
CL (2) CL2016000008A1 (es)
HK (2) HK1223842A1 (es)
IL (3) IL243315B (es)
MX (2) MX2016000122A (es)
NZ (2) NZ716033A (es)
RU (2) RU2633481C2 (es)
SG (2) SG11201510635PA (es)
WO (2) WO2015006319A1 (es)
ZA (1) ZA201600358B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015079016A1 (en) 2013-11-29 2015-06-04 Galderma Sa Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis
WO2016022066A1 (en) 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
FR3032616B1 (fr) * 2015-02-12 2017-02-24 Galderma Sa Compose de la famille des avermectines pour le traitement et/ou la prevention des folliculites
US11213539B2 (en) 2015-11-17 2022-01-04 Galderma Holding SA Use of ivermectin and brimonidine in the treatment and/or prevention of moderate to severe rosacea
EP3493795A1 (en) * 2016-08-04 2019-06-12 Nestlé Skin Health SA Compositions and the use thereof for treating or preventing rosacea
CN106397233A (zh) * 2016-08-26 2017-02-15 南通奥凯生物技术开发有限公司 一种医药级乙二胺四乙酸二钠的制备方法
US11160780B2 (en) * 2016-09-30 2021-11-02 Aurobindo Pharma Ltd. Pharmaceutical composition of ivermectin and process for preparation thereof
AU2018385766B2 (en) 2017-12-15 2022-12-01 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
WO2019241498A1 (en) 2018-06-15 2019-12-19 W. R. Grace & Co.-Conn Defoamer active, manufacturing method thereof, and defoaming formuation
JP7129005B2 (ja) * 2018-09-28 2022-09-01 Toto株式会社 水洗大便器
WO2020172101A1 (en) 2019-02-18 2020-08-27 Mary Kay Inc. Topical skin compositions for treating rosacea and skin redness
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
CN111728959B (zh) * 2020-08-11 2023-02-03 黑龙江天龙药业有限公司 一种抑制油脂分泌且清螨虫的鼻膜贴及其制备方法
EP4062907A1 (fr) 2021-03-23 2022-09-28 Substipharm Formulation par voie orale d'ivermectine et utilisations
WO2022269665A1 (ja) * 2021-06-21 2022-12-29 マルホ株式会社 外用剤
KR102346125B1 (ko) 2021-10-15 2022-01-03 (주)나비바이오텍 이버멕틴 정성 검사용 래피드 키트

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ197796A (en) 1980-08-04 1984-11-09 Merck & Co Inc Stabilised aqueous formulations containing ivermectin
US5332577A (en) 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
US5656280A (en) 1994-12-06 1997-08-12 Helene Curtis, Inc. Water-in-oil-in-water compositions
FR2754452B1 (fr) 1996-10-11 2003-02-14 Oreal Emulsion h/e a forte teneur en electrolytes et leur utilisation en dermo-cosmetique, notamment pour traiter les phenomenes d'irritation et/ou de peaux sensibles
US5952372A (en) 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
FR2787322B1 (fr) 1998-12-18 2002-10-18 Galderma Res & Dev Emulsion huile-dans-eau comprenant un agent actif micronise et un systeme emulsionnant approprie
US6133310A (en) 1999-08-26 2000-10-17 Parks; L. Dean Method of treatment of rosacea
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6399651B1 (en) 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
US6319945B1 (en) 2000-06-29 2001-11-20 L. Dean Parks Method of treatment of seborrheic dermatitis
US6399652B1 (en) 2000-06-29 2002-06-04 L. Dean Parks Method of treating acne vulgaris using avermectin compound
DE10063946A1 (de) 2000-12-20 2002-07-04 Basf Ag Verwendung von Lichtschutzmittelkombinationen, die als wesentlichen Bestandteil 2,2'-p-Phenylen-bis(3,1-benzoxazin-4-on) enthalten als photostabile UV-Filter in kosmetischen und pharmazeutischen Zubereitungen
EP1476121A4 (en) 2002-02-08 2010-10-27 Merck Sharp & Dohme TOPICAL IVERMECTIN COMPOSITION
CN1649578A (zh) 2002-03-04 2005-08-03 戴弗根斯公司 杀线虫的脂肪酸和脂肪酸酯相关化合物
FR2854074B1 (fr) * 2003-04-24 2007-11-23 Galderma Res & Dev Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
WO2004093886A1 (en) 2003-04-24 2004-11-04 Galderma S.A. Topical formulation of ivermectin for the treatment of dermatological conditions
EP1600158A1 (en) 2004-05-26 2005-11-30 Galderma Research & Development, S.N.C. Use of ondansetron for the treatment of inflammation, and pharmaceutical compositions thereof
FR2867684B1 (fr) * 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine
DE602005020912D1 (de) 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme
FR2883181B1 (fr) 2005-03-17 2007-05-18 Galderma Sa Composition a base d'une avermectine et d'acide azelaique notamment pour le traitement de la rosacee
FR2886851B1 (fr) 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
FR2886852B1 (fr) 2005-06-10 2007-11-23 Galderma Sa Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee
FR2886850B1 (fr) 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
FR2894823B1 (fr) 2005-12-20 2008-02-29 Galderma Sa Composition de type emulsion inverse comprenant de l'ivermectine, et ses utilisations en cosmetique et en dermatologie
FR2900052B1 (fr) 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
FR2906468B1 (fr) 2006-09-28 2012-09-21 Galderma Sa Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
FR2907013B1 (fr) 2006-10-12 2012-09-21 Galderma Sa Produits de soin cutane a double compartiment comprenant de l'ivermectine, et leurs utilisations
FR2907012B1 (fr) 2006-10-12 2012-09-21 Galderma Sa Composition dermatologique comprenant des nanocapsules d'avermectine, son procede de preparation et son utilisation
JP2012513387A (ja) 2008-12-23 2012-06-14 ガルデルマ・ソシエテ・アノニム 感水性の活性成分を含む、局所用医薬組成物
EP2391344B1 (en) 2009-01-30 2017-07-12 Yissum Research Development Company of the Hebrew University of Jerusalem Compositions for nail and skin treatment
FR2942138A1 (fr) 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
FR3000397A1 (fr) 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee

Also Published As

Publication number Publication date
CA2916704C (en) 2018-11-20
US20160175337A1 (en) 2016-06-23
US20150011491A1 (en) 2015-01-08
HK1223841A1 (zh) 2017-08-11
JP6653734B2 (ja) 2020-02-26
MX2016000121A (es) 2016-07-14
US20180207188A1 (en) 2018-07-26
US20180177813A1 (en) 2018-06-28
AU2014287422A1 (en) 2016-02-11
WO2015006319A1 (en) 2015-01-15
IL243314A0 (en) 2016-02-29
JP2021059590A (ja) 2021-04-15
IL243315A0 (en) 2016-02-29
US20150011490A1 (en) 2015-01-08
BR112016000350A2 (pt) 2017-07-25
IL274058A (en) 2020-06-30
US20150011489A1 (en) 2015-01-08
US20160143935A1 (en) 2016-05-26
JP2019073527A (ja) 2019-05-16
WO2015006305A1 (en) 2015-01-15
US9233118B2 (en) 2016-01-12
US20210177882A1 (en) 2021-06-17
JP2023052490A (ja) 2023-04-11
IL243314B (en) 2022-02-01
BR112016000350A8 (pt) 2020-01-07
JP2025143422A (ja) 2025-10-01
JP2017197562A (ja) 2017-11-02
KR101864799B1 (ko) 2018-06-05
JP2016526572A (ja) 2016-09-05
NZ716033A (en) 2017-01-27
US20200000835A1 (en) 2020-01-02
ZA201600358B (en) 2019-11-27
AU2014287408B2 (en) 2017-05-04
RU2016103715A (ru) 2017-08-11
KR101863085B1 (ko) 2018-06-01
EP3019173A1 (en) 2016-05-18
US20180264021A1 (en) 2018-09-20
HK1223842A1 (zh) 2017-08-11
CL2016000008A1 (es) 2016-08-05
CN111467301A (zh) 2020-07-31
RU2633076C2 (ru) 2017-10-11
RU2016103753A (ru) 2017-08-11
AU2014287422B2 (en) 2017-04-13
IL274058B (en) 2022-02-01
BR112016000335A8 (pt) 2020-01-07
KR20160061310A (ko) 2016-05-31
CN105828825A (zh) 2016-08-03
JP2016523968A (ja) 2016-08-12
IL243315B (en) 2022-02-01
SG11201510420UA (en) 2016-01-28
US9233117B2 (en) 2016-01-12
US20220347198A1 (en) 2022-11-03
RU2633481C2 (ru) 2017-10-12
AU2014287408A1 (en) 2016-02-11
NZ716034A (en) 2017-01-27
CN111494399A (zh) 2020-08-07
JP2018184437A (ja) 2018-11-22
EP3019174A1 (en) 2016-05-18
MX2016000122A (es) 2016-06-15
US20160184342A1 (en) 2016-06-30
CA2916668A1 (en) 2015-01-15
US10206939B2 (en) 2019-02-19
US9089587B2 (en) 2015-07-28
CN105792829A (zh) 2016-07-20
BR112016000335A2 (pt) 2017-07-25
JP6438466B2 (ja) 2018-12-12
KR20160061311A (ko) 2016-05-31
SG11201510635PA (en) 2016-01-28
CA2916704A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
CL2017003404A1 (es) Compuestos antibacterianos
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
CL2016000925A1 (es) Inhibidores de bromodominio
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
CL2015002658A1 (es) Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio
CL2016002971A1 (es) Combinación.
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
CL2016001737A1 (es) Derivados heterocíclicos bicíclicos como inhibidores de bromodominio
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
UY36075A (es) Derivados de tubulisina
CL2017000394A1 (es) Composición que contiene cineol para la administración nasal
CR20170076A (es) Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2015003019A1 (es) Derivados biaromáticos antibacterianos
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
MX373309B (es) Composiciones antibióticas de ceftolozano.
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
MX2015014713A (es) Uso de una composicion que comprende aceite de pescado y jugo para el tratamiento y/o postratamiento de cancer.